Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Jacqueline B, McCrea"'
Autor:
Karsten Menzel, Yuhsin Kuo, Dapeng Chen, Georgy Hartmann, Ying‐Hong Wang, Carolyn R. Cho, Jacqueline B. McCrea, Kazuhiko Asari
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 6, Pp 1039-1048 (2023)
Abstract Letermovir is approved for use in cytomegalovirus‐seropositive hematopoietic stem cell transplant recipients and is investigated in other transplant settings. Nonlinear pharmacokinetics (PKs) were observed in clinical studies after intrave
Externí odkaz:
https://doaj.org/article/32cc1e5539cc48faa74100d6c7ab7fdf
Autor:
Jacqueline B. McCrea, Karsten Menzel, Craig Fancourt, Rose Witter, Tian Zhao, Jonathan A. Robbins, S. Aubrey Stoch, Marian Iwamoto
Publikováno v:
British Journal of Clinical Pharmacology.
Autor:
Kazuhiko, Asari, Mikio, Ishii, Hiroyuki, Yoshitsugu, Akira, Wakana, Craig, Fancourt, Esther, Yoon, Kenichi, Furihata, Jacqueline B, McCrea, S Aubrey, Stoch, Marian, Iwamoto
Publikováno v:
Clinical Pharmacology in Drug Development. 11:938-948
Letermovir is a human cytomegalovirus terminase inhibitor for the prophylaxis of cytomegalovirus infection and disease in allogeneic hematopoietic stem cell transplant recipients. The pharmacokinetics, safety, and tolerability of letermovir were asse
Autor:
Graigory Garrett, Marian Iwamoto, Jacqueline B. McCrea, John E. Laabs, Azher Hussain, S. Aubrey Stoch, Raymond Evers, Bennett Ma
Publikováno v:
Clinical Pharmacology in Drug Development. 11:406-412
Gefapixant (MK-7264, AF-219), a first-in-class P2X3 antagonist, is being developed as oral treatment for refractory or unexplained chronic cough. Based on in vitro data, gefapixant exerts inhibitory activity on the organic anion transporter (OAT) P1B
Autor:
Karsten Menzel, Jacqueline B. McCrea, Craig Fancourt, Rose Witter, Tian Zhao, S. Aubrey Stoch, Marian Iwamoto
Publikováno v:
British journal of clinical pharmacology.
Letermovir inhibits renal tubular organic anion transporter (OAT)3 in vitro and is predicted to inhibit OAT3 in vivo. Acyclovir, a substrate for OAT3, is likely to be co-administered with letermovir; therefore, letermovir may increase acyclovir conce
Autor:
Stefan Zajic, Monika Martinho, Julie A. Stone, Rose Witter, S. Aubrey Stoch, Jacqueline B. McCrea, Ghassan N. Fayad
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 47:473-484
To develop a framework for evaluating the resorption effects of Cathepsin K (CatK) inhibitors and to inform dose regimen selection, a pharmacokinetic/pharmacodynamic (PK/PD) model for odanacatib (ODN) was developed based upon data from Phase 1 studie
Autor:
Jun Jiang, Shuang Xie, Meng Li, Yudong Wei, Hwa-Ping Feng, Haiyan Li, Xu Min Zhao, Luzelena Caro, Jacqueline B. McCrea, Zhenhua Yang, Shuang Zhang, Jiangdian Wang, Shengmei Mu, Lin Xu
Publikováno v:
Clinical Pharmacology: Advances and Applications. 12:1-11
Purpose The burden of hepatitis C virus infection is particularly high in Asian countries, and new treatments are urgently needed. The purpose of this study was to characterize the pharmacokinetics (PK) and safety of the fixed-dose combination tablet
Autor:
Jonathan A. Robbins, Karsten Menzel, Michael Lassman, Tian Zhao, Craig Fancourt, Xiaoyan Chu, Kate Mostoller, Rose Witter, Rachel Marceau West, S. Aubrey Stoch, Jacqueline B. McCrea, Marian Iwamoto
Publikováno v:
Clinical pharmacology and therapeutics. 111(3)
Rifampin has acute inhibitory and chronic inductive effects that can cause complex drug-drug interactions. Rifampin inhibits transporters including organic-anion-transporting polypeptide (OATP)1B and P-glycoprotein (P-gp), and induces enzymes and tra
Publikováno v:
Br J Clin Pharmacol
Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and localized in the lysosomes and resorption lacunae of these cells. CatK is the principal enzyme responsible for the degradation of bone collagen. Odanacatib is a selecti
Publikováno v:
Current drug metabolism. 22(10)
Background: Letermovir is approved for prophylaxis of cytomegalovirus infection and disease in cytomegalovirus-seropositive hematopoietic stem-cell transplant (HSCT) recipients. Objective: HSCT recipients are required to take many drugs concomitantly